Airports continually balance demands to improve infrastructure within the realities of available budgets. Green revolving funds (GRFs) offer an alternative approach for investing in projects that generate operational savings. These funds work by tracking verified cost reductions from implemented actions, and then transferring those savings to a reserve that provides capital for future qualified projects such as energy system upgrades. A number of universities have managed GRFs for over a decade. Municipa...

EPA announces the availability of the All-Ages Lead Model (AALM), Version 2 software with updated supporting documentation (External Review Draft). The AALM Model is scheduled to undergo an independent peer review by EPA's Science Advisory Board in October 2019. For more information related to scheduling and peer reviewers for this new tool, please visit the SAB AALM Project website. [Federal Register Notice Sep 24, 2019]

A new breed of smart telescopes is set to take users past these hurdles, and get them out under the night sky. We recently had a chance to put Vaonis’ Stellina ‘smart telescope’ through its paces, and we’re intrigued at the glimpse it provides at the future of observational astronomy.

The post Our Review of Stellina: a ‘Smart Telescope’ for 21st Century Astronomy appeared first on Universe Today.

So, you think you know Galileo? A new book out from Simon and Schuster publishing looks at the life and times of one of the most famous astronomers there ever was: Galileo Galilei. Galileo and the Science Deniers by Dr. Mario Livio not only looks at the life and times of the famous astronomer Galileo, but busts some of the most famous myths surrounding Galileo, and looks at his greatest discoveries and tempestuous clash with the Roman Catholic Church and its aftermath. Livio also connects the science denialism of the day, with comparisons to modern clashes between politics and science.

The post Review: Galileo and the Science Deniers by Mario Livio appeared first on Universe Today.

Environmental regulations have long required airports to undertake review of many actions associated with planning and development. More recently, airports have embraced sustainability as a means for ensuring the long-term viability and community benefits of their facilities. The TRB Airport Cooperative Research Program's ACRP Research Report 209: Integrating Sustainability Planning and the Environmental Review Process is designed for airport industry practitioners who are interested in gaining a better ...

Elon Musk has been frustrated that Tesla’s Fremont factory has remained shut down due to Alameda County’s lockdown order, and that anger has apparently reached the boiling point. Musk has claimed that he’ll move Tesla’s headquarters to Nevada or Texa...

TRB 2021 Committee Paper Review will go on as scheduled. The submission site will open June 1 and the deadline is August 1. We have learned a lot during this year’s transition to the TRR Editorial Board workflow for publication papers and have listened to your feedback. Important improvements this year include: • Committee review comments will go to authors by October 31. • Full papers will be posted in the interactive program unless the authors “opt out” because they wish to publish the paper elsewhere....

Množství politiků po celém světě v posledních dnech trápí zásadní otázka. Jak zabránit druhé vlně koronaviru bez škrcení ekonomiky? Možnou cestu ukázalo hlavní město Litvy. Majitelé menších podniků zde museli stejně jako na jiných místech v Evropě dočasně pozastavit svou živnost. Vedení Vilniusu ve snaze zabránit jejich krachu v rámci uvolňovaní restriktivních opatření rozhodlo o umožnění bezplatného využití veřejných prostor.

In lieu of an attendance fee, ID is encouraging donations to nonprofit organizations that we support at the channel, including: the National Center for Missing & Exploited Children, National Network to End Domestic Violence, and One Love.

Most nuclear data measurements are performed at accelerators large enough to occupy a geologic formation a kilometer wide. But a portable device that can reveal the composition of materials quickly on-site would greatly benefit cases such as in archaeology and nuclear arms treaty verification. Research published this week in AIP Advances used computational simulations to show that with the right geometric adjustments, it is possible to perform accurate neutron resonance transmission analysis in a device just 5 meters long.

I live in Stockport, just outside Manchester. It's 10 minutes by train away, but I’m not sure if the trains are running – and in any case I’ve not actually been in my office in Central Manchester since February 20.
That got complex. I was in Iraq for work and came home in early March with a virus. Just not that virus but they wouldn’t test me because Iraq (you know, right next door to Iran) wasn’t on the WHO list.
So. Context. We live in a suburban semi-detatched house with a garden (big for Edgeley). There’s me. Matt the husband.…

My 19 year old cat had to be euthanized a couple of days before Christmas. I must admit the guilt was horrible and all I could do is wonder where my dear

The poster to the left hangs on the wall of my office. Can you figure out the pattern to the sequence? Now you can estimate the size of the nth entry? John Horton Conway died yesterday, a victim of Covid-19. His unique mathematical style combined brilliance and playfulness in equal measure. I came across his […]

Platform.sh removes a major pain point for developers: having to invest time in managing servers, virtual machines, or containers. Instead, Platform.sh enables developers to focus 100% of their time on their code. Since the beginning, Platform.sh has provided instant cloning capability, so dev teams can work on perfect copies of their production sites in the cloud for every Git branch. Now, in partnership with Lando, we’re extending that capability to the desktop.

You may recall in the early days of the pandemic, that pharma giant Gilead Sciences -- which has been accused of price gouging and (just last year!) charging exorbitant prices on drug breakthroughs developed with US taxpayer funds -- was able to sneak through an orphan works designation for its drug remdesevir for COVID-19 treatment. As we pointed out, everything about this was insane, given that orphan works designations, which give extra monopoly rights to the holders (beyond patent exclusivity), are meant for diseases that don't impact a large population. Gilead used a loophole: since the ceiling for infected people to qualify for orphan drug status is 200,000, Gilead got in its application bright and early, before there were 200,000 confirmed cases (we currently have over 1.3 million). After the story went, er... viral, Gilead agreed to drop the orphan status, realizing the bad publicity it was receiving.

After a brief dalliance with chloroquine, remdesivir has suddenly been back in demand as the new hotness of possible COVID-19 treatments. Still, a close reading of the research might give one pause. There have been multiple conflicting studies, and Gilead's own messaging has been a mess.

On April 23, 2020, news of the study’s failure began to circulate. It seems that the World Health Organization (WHO) had posted a draft report about the trial on their clinical trials database, which indicated that the scientists terminated the study prematurely due to high levels of adverse side effects.

The WHO withdrew the report, and the researchers published their results in The Lancet on April 29, 2020.

The number of people who experienced adverse side effects was roughly similar between those receiving remdesivir and those receiving a placebo. In 18 participants, the researchers stopped the drug treatment due to adverse reactions.

But then...

However, also on April 29, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that their NIH trial showed that remdesivir treatment led to faster recovery in hospital patients with COVID-19, compared with placebo treatment.

“Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo,” according to the press release. “Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo.”

The mortality rate in the remdesivir treatment group was 8%, compared with 11.6% in the placebo group, indicating that the drug could improve a person’s chances of survival. These data were close to achieving statistical significance.

And then...

“In addition, there is another Chinese trial, also stopped because the numbers of new patients with COVID-19 had fallen in China so they were unable to recruit, which has not yet published its data,” Prof. Evans continues. “There are other trials where remdesivir is compared with non-remdesivir treatments currently [being] done and results from some of these should appear soon.”

Gilead also put out its own press release about another clinical trial, which seems more focused on determining the optimal length of remdesivir treatment. Suffice it to say, there's still a lot of conflicting data and no clear information on whether or not remdesevir actually helps.

Still, that hasn't stopped people from trying to figure out just how much Gilead will price gouge going forward:

The Institute for Clinical and Economic Review (ICER), which assesses effectiveness of drugs to determine appropriate prices, suggested a maximum price of $4,500 per 10-day treatment course based on the preliminary evidence of how much patients benefited in a clinical trial. Consumer advocacy group Public Citizen on Monday said remdesivir should be priced at $1 per day of treatment, since “that is more than the cost of manufacturing at scale with a reasonable profit to Gilead.”

Some Wall Street investors expect Gilead to come in at $4,000 per patient or higher to make a profit above remdesivir’s development cost, which Gilead estimates at about $1 billion.

So... we've got a range of $10 to $4,500 on a treatment that we don't yet know works, and which may or may not save lives. But, given that we're in the midst of a giant debate concerning things like "reopening the economy" -- something that can really only be done if the public is not afraid of dying (or at least becoming deathly ill) -- the value to the overall economy seems much greater than whatever amount Gilead wants to charge. It seems the right thing to do -- again, if it's shown that remdesevir actually helps -- is to just hand over a bunch of money to Gilead, say "thank you very much" and get the drug distributed as widely as possible. Though, again, it should be noted that a decent chunk of the research around remdesevir was not done or paid for by Gilead, but (yet again) via public funds to public universities, which did the necessary research. The idea that it's Gilead that should get to reap massive rewards for that seems sketchy at best. But the absolute worst outcome is one in which Gilead sticks to its standard operating procedure and prices the drug in a way that millions of Americans can't afford it, and it leads to a prolonging/expanding of the pandemic.

Just posted to Slate, by Isaac Butler: The Disappearance of John M. Ford. Key takeaway to Making Light readers who...

Recent advancements in Machine Learning (ML) have taught us two main lessons: a large proportion of things that humans do can actually be automated, and that a substantial part of this automation can be done with minimal human supervision. One no longer needs to select features for models to use; in many cases people are … Continue reading Three Paper Thursday: Adversarial Machine Learning, Humans and everything in between →

Very '90s kit was everywhere – and it saved Apple's ass too

On this day in 1998, Steve Jobs took to the stage of the Moscone Center in San Francisco for a product launch that would indelibly change the face of computing and arguably save the firm he founded almost 22 years earlier.…

Australia bit barn outfit NEXTDC adds classic film reference to usual mix of resilience, connectivity and security

Australian serial entrepreneur Bevan Slattery has revealed that he told the architects of a data centre he funded to make it resemble the sets used in classic submarine flick The Hunt for Red October.…

At last, we can write headlines with all the letters intact

For a company defined by design and attention to detail, the Butterfly keyboard was a tremendous humiliation for Apple. Conceived in 2015, it replaced the previous scissor-switch mechanism for one with a smaller profile, allowing Cupertino to continue shrinking already-svelte laptops.…

Advertise your open positions here for free, no catch, and find opportunities within

Job Alert This week we've got job openings from all over the globe to tempt you, your friends or your past colleagues back into work, or indeed into new ventures.…

Virus knocks hackers online: Show will try going virtual amid pandemic

Annual Las Vegas hacker gathering DEF CON has officially called off its physical conference for this year due to the coronavirus pandemic.…

Nice way to get to Alpha Centauri though boffin tells us: 'Such a laser system could be used as a weapon'

Coin-sized pieces of graphene can be accelerated by firing low-powered lasers at them in micro-gravity conditions, say scientists. The technology could be a stepping stone to graphene solar sails, which could propel future spacecraft using starlight or a laser array.…